9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Virus particles in respiratory droplets and aerosols generated during medical/dental procedures are a potential source of SARS-CoV-2 cross infection. In the dental setting, oral decontamination could be an important adjunct to personal protective equipment and is recommended by a number of national COVID-19 guidance documents for dental settings.

          Aim To assess the in vitrovirucidal activity of an oral povidone iodine (PVP-I) product against SARS-CoV-2.

          Material and methods BETADINE gargle and mouthwash (1% PVP-I) was tested against SARS-CoV-2 virus under both clean and dirty conditions using a suspension assay based on EN14476 methodology. Virucidal activity of the product, undiluted and at 1:2 dilution, was tested at contact times of 15, 30 and 60 seconds. Viral titres were calculated using the Spearman-Kärber method and reported as median tissue culture infectious dose (TCID 50/ml).

          Results The undiluted product achieved >5 log10 reduction in viral titres compared to the control at 15, 30 and 60 seconds under both clean and dirty conditions. At a twofold dilution (0.5% PVP-I), the test product demonstrated >4 log10 kill at 15 seconds and >5 log10 kill at 30 and 60 seconds in both clean and dirty conditions.

          Conclusion PVP-I gargle and mouthwash product, undiluted and at 1:2 dilution, demonstrated potent and rapid virucidal activity (≥4 log10 reduction of viral titre) in 15 seconds against SARS-CoV-2 in vitro. The PVP-I gargle and mouthwash product is widely available and could be readily integrated into infection control measures during dental treatment including pre-procedural oral decontamination.

          Key points

          • Close contact and potential for aerosol generation increase risk of SARS-CoV-2 exposure during medical and dental procedures.

          • Pre-procedural mouth rinses are recommended as an additional measure to reduce cross-infection risk in dental settings.

          • PVP-I (1%) gargle and mouthwash showed 99.99% kill rate of SARS-CoV-2 in vitro within 15 seconds of contact in clean and dirty conditions.

          • The use of PVP-I-containing pre-procedural mouth rinse to reduce oral viral load could be recommended in addition to other protective measures.

          Related collections

          Author and article information

          Contributors
          pouyahassandarvish@um.edu.my
          Journal
          Br Dent J
          Br Dent J
          British Dental Journal
          Nature Publishing Group UK (London )
          0007-0610
          1476-5373
          10 December 2020
          : 1-4
          Affiliations
          [1 ]GRID grid.10347.31, ISNI 0000 0001 2308 5949, Tropical Infectious Diseases Research and Education Centre (TIDREC), ; University of Malaya, Malaysia
          [2 ]GRID grid.462995.5, ISNI 0000 0001 2218 9236, Basic Medical Sciences 2 Department, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, 55100 Pandan Indah, ; Kuala Lumpur, Malaysia
          [3 ]Mundipharma Singapore Holding Pte Limited, Singapore
          Article
          2402
          10.1038/s41415-020-2402-0
          7726738
          0fdae47d-11d5-4bb5-bd2b-91657e3fe1fa
          © British Dental Association 2020

          This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

          History
          : 19 August 2020
          : 02 November 2020
          Categories
          Research

          Comments

          Comment on this article